Fintech solutions provider Jirnexu has acquired Malaysia’s CompareHero while Singapore’s Hasten Biopharma said it has secured the rights to 14 Celltrion products.
Jirnexu acquires CompareHero in Malaysia
RinggitPlus operator Jirnexu has acquired CompareHero, a subsidiary of Nasdaq-listed personal finance and digital insurance aggregator MoneyHero Limited, according to an announcement.
Financial details of the deal, which is expected to close this month, were not disclosed. The announcement said the deal includes CompareHero’s website and domain names as well as select user data and IP rights.
MoneyHero will retain an equity stake in Jirnexu Pte. Ltd., the parent company of Jirnexu, ensuring its continued involvement in the Malaysian market, per the announcement.
CompareHero was launched in 2013 by MoneyHero and quickly became one of the top platforms in Malaysia for comparing personal finance products.
Jirnexu, on the other hand, was founded in 2013 as a full-stack fintech solution provider that empowers financial institutions and service providers with customer acquisition and lifecycle management solutions.
SG’s Hasten Biopharma acquires 14 Celltrion products
Hasten Biopharmaceutical, backed by CBC Group, Asia’s largest healthcare-dedicated asset management firm, has announced the acquisition of the asset rights of 14 branded products of its South Korean counterpart Celltrion.
The acquisition will see Hasten owning the marketing authorisation holder rights for these 14 products in eight countries and regions, including South Korea, Singapore, Thailand, Australia, and China Hong Kong SAR.
Financial details of the deal were not disclosed.
Hasten said the acquisition will expand its product portfolios, with the commercial rights to drugs in various chronic diseases areas such as hypertension and diabetes, including Edarbi, Basen, Actos, Blopress, and Nesina.
“This successful acquisition marks an important step as we expand our business across pan-Asia and progress towards our globalisation trajectory,” said Hasten CEO Summer Xia.
